[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-associated-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-associated-thrombosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100458852","phase-4-strategies-for-anticoagulation-in-patients-with-thrombocytopenia-and-cancer-associated-thrombosis-100458852",false,"NCT05255003","STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","Inclusion Criteria:\n\n1. Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive\u002Frelapsed);\n2. Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned;\n3. Thrombocytopenia with a platelet count \\\u003C 50,000\u002FuL from cancer therapy or malignancy itself;\n4. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Receipt of anticoagulant for index VTE with platelet count \\\u003C 50,000\u002FuL for \\> 72 hours;\n2. Superficial vein thrombosis only;\n3. Life expectancy \\\u003C 1 month (as judged by the treating physicians);\n4. Creatinine clearance \\\u003C 30 ml\u002Fmin;\n5. Contraindication to LMWH such as a history of heparin induced thrombocytopenia;\n6. Thrombocytopenia from other causes, such as thrombotic microangiopathy, immune thrombocytopenia, disseminated intravascular coagulation;\n7. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies;\n8. Refusal of blood products;\n9. Anticoagulation at any dose is deemed unsafe (i.e. active bleeding or bleeding disorders)","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and\u002For cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts.\n\nThe investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 2 weeks. Patients will be randomly assigned to one of the two treatment strategies: the full dose of blood thinners along with platelet transfusion or a reduced dose of blood thinners without platelet transfusion. The investigators will follow all patients for 30 days. If this pilot study is successful, it will help lead to a much larger trial, which will provide important information on the best treatment strategy for these patients.",[25,26],"Cancer-associated Thrombosis","Thrombocytopenia","RECRUITING","2025-12-09",{"date":30,"type":31},"2025-12-17","ACTUAL",{"date":33,"type":31},"2022-08-29",{"date":35,"type":19},"2027-01-31",{"name":37,"class":38},"Tzu-Fei Wang","OTHER",4,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":61},"100584839","development-of-a-risk-stratification-score-for-recurrent-venous-thromboembolism-and-treatment-related-clinically-relevant-bleeding-in-patients-with-cancer-associated-thrombosis-100584839","NCT06894576","Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis","CAN-CATCH","Inclusion Criteria:\n\n* Objectively documented distal and\u002For proximal DVT of the limb (upper or lower extremity) and\u002For PE, splanchnic vein thrombosis and\u002For cerebral sinus vein thrombosis in presence of active cancer of all types\n* Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.\n* Estimated life expectancy \\> 6 months\n* Willingness to give an informed consent\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)\n* Superficial vein thrombosis\n* Refusal of informed consent \\> 72 hrs of anticoagulants\n* Age \\\u003C 18 years old",{"count":48,"type":19},1000,"OBSERVATIONAL","The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.",[25],"2025-03-18",{"date":54,"type":31},"2025-03-25",{"date":56,"type":31},"2024-12-03",{"date":58,"type":19},"2027-12",{"name":60,"class":38},"Ottawa Hospital Research Institute",1,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":16,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":73,"conditions":74,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":61},"100537939","the-gynecological-cancer-associated-thrombosis-gyncat-study-100537939","NCT06284343","The Gynecological Cancer Associated Thrombosis (GynCAT) Study","Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study","GynCAT","Inclusion Criteria:\n\n* Female sex;\n* Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);\n* Planned new line of systemic antineoplastic treatment;\n* Age of 18 years or older;\n* Accordance of Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women;\n* Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);\n* Diagnosis of symptomatic VTE at the time of screening for enrollment.","FEMALE",{"count":72,"type":19},1800,"GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.",[25,75,76,77,78,79,80],"Venous Thromboembolism","Gynecologic Cancer","Ovarian Cancer","Cervix Cancer","Endometrial Cancer","Vaginal Cancer",[82,83,84,77,80,79,76],"Thrombosis","Venous thromboembolism","Cancer","2024-09-17",{"date":87,"type":31},"2024-09-19",{"date":89,"type":31},"2024-04-15",{"date":91,"type":19},"2026-09-30",{"name":93,"class":38},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]